BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 11933754)

  • 21. Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran).
    Ramakrishna R; Manoharan A; Kwan YL; Kyle PW
    Br J Haematol; 1995 Nov; 91(3):736-8. PubMed ID: 8555084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight.
    Grims RH; Weger W; Reiter H; Arbab E; Kränke B; Aberer W
    Br J Dermatol; 2007 Sep; 157(3):514-7. PubMed ID: 17573880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arthus reaction to lepirudin, a new recombinant hirudin, and delayed-type hypersensitivity to several heparins and heparinoids, with tolerance to its intravenous administration.
    Jappe U; Reinhold D; Bonnekoh B
    Contact Dermatitis; 2002 Jan; 46(1):29-32. PubMed ID: 11918584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparin-induced thrombocytopenia: pathophysiology and management.
    Mureebe L; Silver D
    Vasc Endovascular Surg; 2002; 36(3):163-70. PubMed ID: 12075381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eczematous plaques related to unfractionated and low-molecular-weight heparin in pregnancy: cross-reaction with danaparoid sodium.
    Blickstein D; Hod M; Bar J
    Blood Coagul Fibrinolysis; 2003 Dec; 14(8):765-8. PubMed ID: 14614358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin.
    Lubenow N; Greinacher A
    J Thromb Thrombolysis; 2000 Nov; 10 Suppl 1():47-57. PubMed ID: 11155194
    [No Abstract]   [Full Text] [Related]  

  • 27. [Successful therapy of heparin-associated thrombocytopenia with a low sulfated heparinoid].
    Herzog S; Rath W; Kuhn W
    Geburtshilfe Frauenheilkd; 1995 Mar; 55(3):164-6. PubMed ID: 7665065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
    Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
    Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed-type hypersensitivity skin reactions caused by subcutaneous unfractionated and low-molecular-weight heparins: tolerance of a new recombinant hirudin.
    Koch P; Münssinger T; Rupp-John C; Uhl K
    J Am Acad Dermatol; 2000 Apr; 42(4):612-9. PubMed ID: 10727306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparin-induced thrombocytopenia and its treatment.
    Warkentin TE
    J Thromb Thrombolysis; 2000 Jun; 9 Suppl 1():S29-35. PubMed ID: 10859582
    [No Abstract]   [Full Text] [Related]  

  • 31. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery.
    Koster A; Meyer O; Hausmann H; Kuppe H; Hetzer R; Mertzlufft F
    J Clin Anesth; 2000 Jun; 12(4):324-7. PubMed ID: 10960207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Heparin-induced thrombocytopenia].
    Depasse F; Samama MM
    Ann Biol Clin (Paris); 2000; 58(3):317-26. PubMed ID: 10846236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of allergy to heparins in postoperative care: subcutaneous allergy and intravenous tolerance.
    Seitz CS; Brocker EB; Trautmann A
    Dermatol Online J; 2008 Sep; 14(9):4. PubMed ID: 19061586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thromboembolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reactivity to a low molecular weight heparin-treatment with Org 10172 (Lomoparan).
    Muhm M; Claeys L; Huk I; Koppensteiner R; Kyrle PA; Minar E; Stümpflen A; Ehringer H; Polterauer P
    Wien Klin Wochenschr; 1997 Feb; 109(4):128-31. PubMed ID: 9076930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Delayed intracutaneous test reaction in heparin intolerance].
    Wurpts G; Merk HF
    Hautarzt; 2007 May; 58(5):394-6. PubMed ID: 17450341
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia].
    Chirurg; 1998 Nov; 69(11 Suppl Massnahme):1-4. PubMed ID: 9853175
    [No Abstract]   [Full Text] [Related]  

  • 37. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans.
    Ludwig RJ; Beier C; Lindhoff-Last E; Kaufmann R; Boehncke WH
    Contact Dermatitis; 2003 Sep; 49(3):158-9. PubMed ID: 14678213
    [No Abstract]   [Full Text] [Related]  

  • 38. [Current status of anticoagulants].
    Oger E; Mottier D
    Presse Med; 2000 May 27-Jun 3; 29(19):1079-82. PubMed ID: 10874921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delayed hypersensitivity skin reaction to enoxaparin.
    Méndez J; de la Fuente R; Stolle R; Vega JM; Sanchís ME; Armentia A; Sánchez P; Fernández A
    Allergy; 1996 Nov; 51(11):853-4. PubMed ID: 8947349
    [No Abstract]   [Full Text] [Related]  

  • 40. Platelet aggregation in response to four low molecular weight heparins and the heparinoid ORG 10172 in patients with heparin-induced thrombocytopenia.
    Keeling DM; Richards EM; Baglin TP
    Br J Haematol; 1994 Feb; 86(2):425-6. PubMed ID: 7515270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.